Experiences With and Challenges Afforded by Expedited Regulatory Pathways

Clin Pharmacol Ther. 2019 Apr;105(4):795-797. doi: 10.1002/cpt.1365.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Costs and Cost Analysis / economics*
  • Drug Approval / economics*
  • Drug Industry / economics*
  • Humans
  • Prescription Drugs / economics*
  • Time Factors

Substances

  • Prescription Drugs